Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 11/20 | 0.37 |
| ▸ | ESR1 | P03372 | 8/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.30 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4810769 | 0.89 | PDK2 (0.33) | ESR2ESR1GRIN2B | |
| SCHEMBL4818565 | 0.88 | KDM4E (0.36) | ESR2ESR1CYP26A1CYP26B1 | |
| SCHEMBL17539089 | 0.80 | ESR2 (0.35) | ESR2ESR1 | |
| SCHEMBL30583476 | 0.76 | GRIN2B (0.34) | ESR2ESR1GRIN2BCYP4F2CYP4A11 | |
| SCHEMBL9049281 | 0.76 | MAP3K14 (0.38) | CYP26A1CYP26B1 | |
| SCHEMBL12491381 | 0.76 | ESR2 (0.47) | ESR2ESR1CYP26A1CYP26B1 | |
| SCHEMBL4817625 | 0.75 | KDM1A (0.40) | — | |
| SCHEMBL16977657 | 0.73 | ESR2 (0.39) | ESR2ESR1GRIN2BEP300CREBBP | |
| SCHEMBL4814771 | 0.72 | ESR1 (0.33) | ESR2ESR1 | |
| SCHEMBL4816490 | 0.72 | ESR1 (0.33) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1740579-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | ESR2 2618/4885ESR1 3300/4885GRIN2B 2182/4885 |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | ESR2 2286/4885ESR1 3443/4885GRIN2B 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.